Long-term chamomile (Matricaria chamomilla L.) treatment for generalized anxiety disorder: A randomized clinical trial

Phytomedicine

Volumn 23, Issue 14, 2016, Pages 1735-1742

  Mao, Jun J ^a   Xie, Sharon X ^b   Keefe, John R ^c   Soeller, Irene ^b   Li, Qing S ^b   Amsterdam, Jay D ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Chamomile; Clinical trials; Generalized anxiety disorder; Herbal medicine

Indexed keywords

CHAMOMILE; PLACEBO; ANXIOLYTIC AGENT; PLANT EXTRACT;

ADULT; ARTICLE; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FLUSHING; FOLLOW UP; GENERALIZED ANXIETY DISORDER; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MATRICARIA CHAMOMILLA; MEAN ARTERIAL PRESSURE; OPEN STUDY; OUTPATIENT; PARASOMNIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RELAPSE; SIDE EFFECT; THROMBOCYTE COUNT; TREATMENT DURATION; URINARY FREQUENCY; VITAL SIGN; VIVID DREAM; XEROSTOMIA; ANXIETY; ANXIETY DISORDERS; BLOOD PRESSURE; DRUG EFFECTS; MATRICARIA; MIDDLE AGED; PHYTOTHERAPY; RECURRENT DISEASE; TIME FACTOR; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; ANTI-ANXIETY AGENTS; ANXIETY; ANXIETY DISORDERS; BLOOD PRESSURE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MATRICARIA; MIDDLE AGED; PHYTOTHERAPY; PLANT EXTRACTS; RECURRENCE; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84994559365     PISSN: 09447113     EISSN: 1618095X     Source Type: Journal    
DOI: 10.1016/j.phymed.2016.10.012     Document Type: Article

References (37)

1. Allgulander, C., Florea, I., Huusom, A.K., Prevention of relapse in generalized anxiety disorder by escitalopram treatment. Int. J. Neuropsychopharmacol. 9 (2006), 495–505.
2. Amsterdam, J.D., Brunswick, D.J., Gibertini, M., Sustained efficacy of gepirone-IR in major depressive disorder: a double-blind placebo substitution trial. J. Psychiatr. Res. 38 (2004), 259–265.
3. Amsterdam, J.D., Li, Y., Soeller, I., Rockwell, K., Mao, J.J., Shults, J., A randomized, double-blind, placebo-controlled trial of oral Matricaria recutita (chamomile) extract therapy for generalized anxiety disorder. J. Clin. Psychopharmacol. 29 (2009), 378–382.
4. Andrews, G., Hobbs, M.J., Borkovec, T.D., Beesdo, K., Craske, M.G., Heimberg, R.G., Rapee, R.M., Ruscio, A.M., Stanley, M.A., Generalized worry disorder: a review of DSM-IV generalized anxiety disorder and options for DSM-V. Depress. Anxiety 27 (2010), 134–147.
5. Beck, A.T., Epstein, N., Brown, G., Steer, R.A., An inventory for measuring clinical anxiety: psychometric properties. J. Consult. Clin. Psychol. 56 (1988), 893–897.
6. Bystritsky, A., Hovav, S., Sherbourne, C., Stein, M.B., Rose, R.D., Campbell-Sills, L., Golinelli, D., Sullivan, G., Craske, M.G., Roy-Byrne, P.P., Use of complementary and alternative medicine in a large sample of anxiety patients. Psychosomatics 53 (2012), 266–272.
7. Davidson, J.R., Bose, A., Korotzer, A., Zheng, H., Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study. Depress. Anxiety 19 (2004), 234–240.
8. Davidson, J.R., Wittchen, H.U., Llorca, P.M., Erickson, J., Detke, M., Ball, S.G., Russell, J.M., Duloxetine treatment for relapse prevention in adults with generalized anxiety disorder: a double-blind placebo-controlled trial. Eur. Neuropsychopharmacol. 18 (2008), 673–681.
9. Fava, M., Weight gain and antidepressants. J. Clin. Psychiatry 11:61 Suppl (2000), 37–41.
10. First, M.S., Spitzer, L., Gibbon, M., Williams, J., Structured clinical interview for DSM-IV-TR axis I disorders (SCID-I/P W/PSY screen). Biometrics Research, 2001, New York State Psychiatric Institute, New York, NY.
11. Gelenberg, A.J., Lydiard, R.B., Rudolph, R.L., Aguiar, L., Haskins, J.T., Salinas, E., Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: a 6-month randomized controlled trial. JAMA 283 (2000), 3082–3088.
12. Guy, W., Assessment Manual for Psychopharmacology. DHEW Publication ADM, pp., 1976, 76–338.
13. Hamilton, M., The assessment of anxiety states by rating. Br. J. Med. Psychol 32 (1959), 50–55.
14. Keefe, J.R., Mao, J.J., Soeller, I., Li, Q.S., Amsterdam, J.D., Short-term open-label chamomile (Matricaria chamomilla L.) therapy of moderate to severe generalized anxiety disorder. Phytomedicine., 2016, 10.1016/j.phymed.2016.10.013.
15. Keller, M.B., The long-term clinical course of generalized anxiety disorder. J. Clin. Psychiatry 8:63 Suppl (2002), 11–16.
16. Kessler, R.C., Berglund, P., Demler, O., Jin, R., Merikangas, K.R., Walters, E.E., Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the national comorbidity survey replication. Arch. Gen. Psychiatry 62 (2005), 593–602.
17. Kessler, R.C., DuPont, R.L., Berglund, P., Wittchen, H.U., Impairment in pure and comorbid generalized anxiety disorder and major depression at 12 months in two national surveys. Am. J. Psychiatry 156 (1999), 1915–1923.
18. Kessler, R.C., Soukup, J., Davis, R.B., Foster, D.F., Wilkey, S.A., Van Rompay, M.I., Eisenberg, D.M., The use of complementary and alternative therapies to treat anxiety and depression in the United States. Am. J. Psychiatry 158 (2001), 289–294.
19. Mao, J.J., Li, Q.S., Soeller, I., Rockwell, K., Xie, S.X., Amsterdam, J.D., Long-term chamomile therapy of generalized anxiety disorder: a study protocol for a randomized, double-blind, placebo-controlled trial. J. Clin. Trials, 4, 2014, 188, 10.4172/2167-0870.1000188.
20. McIntyre, E., Saliba, A.J., Moran, C.C., Herbal medicine use in adults who experience anxiety: a qualitative exploration. Int. J. Qual. Stud. Health well-being, 10, 2015, 29275.
21. Mitte, K., Noack, P., Steil, R., Hautzinger, M., A meta-analytic review of the efficacy of drug treatment in generalized anxiety disorder. J. Clin. Psychopharmacol. 25 (2005), 141–150.
22. Montejo, A.L., Llorca, G., Izquierdo, J.A., Rico-Villademoros, F., Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish working group for the study of psychotropic-related sexual dysfunction. J. Clin. Psychiatry 62:Suppl 3 (2001), 10–21.
23. Montgomery, S.A., Kennedy, S.H., Burrows, G.D., Lejoyeux, M., Hindmarch, I., Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study. Int. Clin. Psychopharmacol. 19 (2004), 271–280.
24. Montgomery, S.A., Sheehan, D.V., Meoni, P., Haudiquet, V., Hackett, D., Characterization of the longitudinal course of improvement in generalized anxiety disorder during long-term treatment with venlafaxine XR. J. Psychiatr. Res. 36 (2002), 209–217.
25. Nakazawa, T., Yasuda, T., Ueda, J., Ohsawa, K., Antidepressant-like effects of apigenin and 2,4,5-trimethoxycinnamic acid from Perilla frutescens in the forced swimming test. Biol. Pharm. Bull. 26 (2003), 474–480.
26. National Institute of Mental Health. Treatment emergent symptoms scale. Psychopharmacol. Bull. 21 (1985), 1069–1073.
27. Raudenbush, S.W., Bryk, A.S., Hierarchical Linear Models: Applications and Data Analysis Methods. second ed, 2002, Sage Publications, Thousand Oaks, California.
28. Reinhold, J.A., Rickels, K., Pharmacological treatment for generalized anxiety disorder in adults: an update. Expert Opin. Pharmacother. 16 (2015), 1669–1681.
29. Reis, L.S., Pardo, P.E., Oba, E., Kronka Sdo, N., Frazatti-Gallina, N.M., Matricaria chamomilla CH12 decreases handling stress in Nelore calves. J. Vet. Sci. 7 (2006), 189–192.
30. Rickels, K., Etemad, B., Khalid-Khan, S., Lohoff, F.W., Rynn, M.A., Gallop, R.J., Time to relapse after 6 and 12 months’ treatment of generalized anxiety disorder with venlafaxine extended release. Arch. Gen. Psychiatry 67 (2010), 1274–1281.
31. Salamon, I., Chamomile, a medicinal plant. Herb Spice Med. Plant Digest 10 (1992), 1–4.
32. Spitzer, R.L., Kroenke, K., Williams, J.B.W., Lowe, B., A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch. Intern. Med. 166 (2006), 1092–1097.
33. Stein, D.J., Ahokas, A., Albarran, C., Olivier, V., Allgulander, C., Agomelatine prevents relapse in generalized anxiety disorder: a 6-month randomized, double-blind, placebo-controlled discontinuation study. J. Clin. Psychiatry 73 (2012), 1002–1008.
34. Stocchi, F., Nordera, G., Jokinen, R.H., Lepola, U.M., Hewett, K., Bryson, H., Iyengar, M.K., Efficacy and tolerability of paroxetine for the long-term treatment of generalized anxiety disorder. J. Clin. Psychiatry 64 (2003), 250–258.
35. Walker, J.R., Van Ameringen, M.A., Swinson, R., Bowen, R.C., Chokka, P.R., Goldner, E., Johnston, D.C., Lavallie, Y.J., Nandy, S., Pecknold, J.C., Hadrava, V., Lane, R.M., Prevention of relapse in generalized social phobia: results of a 24-week study in responders to 20 weeks of sertraline treatment. J. Clin. Psychopharmacol. 20 (2000), 636–644.
36. Wiklund, I., Holst, J., Karlberg, J., Mattsson, L.A., Samsioe, G., Sandin, K., Uvebrant, M., von Schoultz, B., A new methodological approach to the evaluation of quality of life in postmenopausal women. Maturitas 14 (1992), 211–224.
37. Yonkers, K.A., Bruce, S.E., Dyck, I.R., Keller, M.B., Chronicity, relapse, and illness–course of panic disorder, social phobia, and generalized anxiety disorder: findings in men and women from 8 years of follow-up. Depress. Anxiety 17 (2003), 173–179.